Engagement of Mesenchymal Stromal Cells in the Remodeling of Bone Marrow Microenvironment in Hematological Cancers
Authors:
- Sebastiano GiallongoSGSebastiano Giallongo
- Andrea DuminucoAndrea Duminuco
- Ilaria DulcamareIDIlaria Dulcamare
- Tatiana ZuppelliTZTatiana Zuppelli
- Enrico La SpinaESEnrico La Spina
- Grazia ScanduraGSGrazia Scandura
- Annalisa SantisiASAnnalisa Santisi
- Alessandra RomanoAlessandra Romano
- Francesco Di RaimondoFRFrancesco Di Raimondo
- Daniele TibulloDaniele Tibullo
- Giuseppe Alberto PalumboGiuseppe Alberto Palumbo
- Cesarina GiallongoCGCesarina Giallongo
Preprint
- 1 November 2023
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Mesenchymal stromal cells (MSCs) are a subset of heterogeneous non-hematopoietic fibro-blast-like cells which play important roles in tissue repair, inflammation, and immune modula-tion. MSCs residing in the bone marrow microenvironment (BMME) functionally interact with hematopoietic stem progenitor cells regulating hematopoiesis. However, MSCs have also emerged in the last years as key regulator of tumor microenvironment. Indeed, they are now con-sidered as active players in the pathophysiology of hematologic malignancies rather than passive by-standers in hematopoietic microenvironment. Once the malignant event occurs, the BMME acquires cellular, molecular, and epigenetic abnormalities affecting tumor growth and progres-sion. In this context, MSC behavior is affected by signals coming from cancer cells. Furthermore, it has been showed that stromal cells themselves play a major role in several hematological malig-nancies’ pathogenesis. This bidirectional crosstalk creates a functional tumor niche unit wherein tumor cells acquire a selective advantage over their normal counterpart and are protected from drug treatment. It is therefore of critical importance to unveil the underlying mechanisms which activate a protumor phenotype of MSCs for defining unmasked vulnerabilities of hematological cancer cells which could be pharmacologically exploited to disrupt the tumor/MSCs coupling. The present review will focus on the current knowledge about MSC dysfunction mechanisms in the BMME of hematological cancers, sustaining tumor growth, immune escape, and cancer pro-gression.Keywords
All Related Versions
- Version 1, 2023-11-01, Preprints
- Published version: Biomolecules, 13 (12), 1701.
This publication has 211 references indexed in Scilit:
- CD155/TIGIT signalling plays a vital role in the regulation of bone marrow mesenchymal stem cell–induced natural killer–cell exhaustion in multiple myelomaClinical and Translational Medicine, 2022
- Acute Myeloid Leukemia Cells Educate Mesenchymal Stromal Cells toward an Adipogenic Differentiation Propensity with Leukemia Promotion CapabilitiesAdvanced Science, 2022
- Bone marrow‐mesenchymal stem cell‐derived extracellular vesicles affect proliferation and apoptosis of leukemia cells in vitroFEBS Open Bio, 2021
- Adipose‐derived mesenchymal stem cells differentiate into pancreatic cancer‐associated fibroblasts in vitroFEBS Open Bio, 2020
- Alteration of cellular and immune‐related properties of bone marrow mesenchymal stem cells and macrophages by K562 chronic myeloid leukemia cell derived exosomesJournal of Cellular Physiology, 2018
- Metabolic underpinnings of leukemia pathology and treatmentCancer Reports, 2018
- Commitment to Aerobic Glycolysis Sustains Immunosuppression of Human Mesenchymal Stem CellsStem Cells Translational Medicine, 2018
- The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cellsAmerican Journal of Hematology, 2018
- Identification of Senescent Cells in the Bone MicroenvironmentJournal of Bone and Mineral Research, 2016
- Functional Niche Competition Between Normal Hematopoietic Stem and Progenitor Cells and Myeloid Leukemia CellsStem Cells, 2015